Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

ody platform with the publication of data in Nature Medicine showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.
  • Entered into a five-year contract potentially worth up to $44.4 million with the Department of Defense's Defense Threat Reduction Agency (DTRA), and ramped up activities under this contract to assess bavituximab and other anti-PS antibodies for biodefense applications against viral hemorrhagic fevers.
  • Continued to enroll and dose patients in an ongoing Phase I clinical trial of bavituximab in hepatitis C virus infected patients co-infected with HIV.
  • Was awarded a U.S. patent that includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids, including PS.
  • Reported that the company's anti-PS technology was positively highlighted in scientific sessions at the AIDS Vaccine 2008 conference in Cape Town, South Africa.
  • Cotara(R) Brain Cancer Program

    • Reported that patient enrollment in the Cotara dosing and dosimetry trial at U.S. brain cancer centers was nearing completion, and that patients in the initial two cohorts of the study have all either met or exceeded the expected median survival time of six months for recurrent glioblastoma multiforme (GBM) patients.
    • Presented data at the Society of Nuclear Medicine 2009 Annual Meeting showing that Cotara specifically localizes to brain tumors at high concentrations with minimal radiation exposure to other organs. This data confirms a key safety attribute of Cotara - its ability to precisely target tumors. Data showed that the concentration of Cotara in brain tumors was on average more than 300-fold higher than in normal organs.
    • Reported that patient enrollment has exceeded the halfway mark in the Cotara Phase II trial in patients with relapsed GBM.
      '/>"/>

    SOURCE Peregrine Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine news :

    1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
    2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
    3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
    4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
    5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
    6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
    7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
    8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
    9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
    10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
    11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/18/2014)... 18, 2014 -- BGI Tech Solutions Co., LTD., ... DLF-Trifolium and the Department of Molecular Biology and ... to develop a series of new high-yielding forage ... , GS is a new form of marker ... QTL-based selection, uses information equally from all available ...
    (Date:9/18/2014)... VA (PRWEB) September 18, 2014 ... The organization’s first ever digital edition – rich ... the story of how CRDF Global empowers scientists ... diverse network of government, corporate, foundation and individual ... scientists and innovators in research, training and entrepreneurship. ...
    (Date:9/18/2014)... September 18, 2014 Research conducted by ... Allegheny Health Network has documented improved survival in ... removal of the tumors along with stereotactic radiosurgery. , ... ASTRO (American Society for Radiation Oncology) this ... numerous precisely focused radiation beams to treat tumors in ...
    (Date:9/18/2014)... South Africa (PRWEB) September 18, 2014 ... to adopt the HABIT™ Program in South ... Indaba Health and Wellness, and distributed in South Africa ... of the HABIT program, which has been tailored to ... IHW HABIT™ focuses on behavior modification and chronic disease ...
    (Date:9/18/2014)... This past August, Narconon Louisiana New Life Retreat CEO Cathy ... during the West Feliciana Animal Humane Society fundraiser to support the ... my whole life and have always had animals as part of ... a home. Supporting an animal shelter allows me to help ... The CEO of Narconon Louisiana was there not only to lend ...
    Breaking Medicine News(10 mins):Health News:BGI Tech, DLF-Trifolium A/S, and Aarhus University applying genomic selection methods 2Health News:CRDF Global Launches Media-Rich Digital Edition of Annual Report, Tells Story of Empowering Scientists and Innovators around the World in 2013 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2
    ... its 10th year, the ESMO International Symposium: ... received endorsements from 6 leading professional societies ... Congress as the premier platform for specialists ... clinicians to review the state-of-the-art in gastrointestinal ...
    ... -- China Sky One,Medical, Inc. (Amex: ... Company"), a China-based,manufacturer, marketer and distributor of ... that its wholly-owned subsidiary,Harbin First Bio-Engineering Pharmaceutical ... development center by the Science and Technology,Institute ...
    ... Brookdale Senior,Living Inc. (NYSE: BKD ) announced today ... the 2008 Jefferies Healthcare,Conference in New York, New York ... The presentation is being webcast live and can ... website at, http://www.brookdaleliving.com . A replay of the webcast ...
    ... for ... health plans, WOONSOCKET, R.I., June ... Health Insurance Plans,(AHIP) Institute 2008 to be held June 18-20, 2008 in ... Consumer,Experience" will discuss ways in which health plans can take a proactive,approach ...
    ... MIAMI and LOS ANGELES, June 19 Cardo ... orthopedic medical devices,and clickNsettle.com, Inc. (OTC Bulletin Board: ... signed a merger agreement pursuant,to which Cardo Medical ... the merger is completed, clickNsettle will be renamed,Cardo ...
    ... up with Minor League Baseball(TM) to raise awareness of, Benign ... ... U.S., BRIDGEWATER, N.J., June 19 Hall of Fame third,baseman and ... to launch BPH Game Plan Starts with U:,Catch the Whole Game campaign, ...
    Cached Medicine News:Health News:10th World Congress on Gastrointestinal Cancer -- Barcelona, Spain 2Health News:China Sky One Medical, Inc. Research Center Recognized by Heilongjiang Science and Technology Institute 2Health News:China Sky One Medical, Inc. Research Center Recognized by Heilongjiang Science and Technology Institute 3Health News:CVS Caremark to Present Insights on Redefining the Consumer Health Care Experience at AHIP Institute 2008 2Health News:CVS Caremark to Present Insights on Redefining the Consumer Health Care Experience at AHIP Institute 2008 3Health News:clickNsettle.com, Inc. and Cardo Medical, LLC Announce Merger Agreement 2Health News:clickNsettle.com, Inc. and Cardo Medical, LLC Announce Merger Agreement 3Health News:Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men 2Health News:Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men 3Health News:Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men 4Health News:Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men 5
    (Date:9/18/2014)... 18, 2014  Spring Bank Pharmaceuticals, Inc., a ... treatment of RNA viruses, today announced a research ... for animal testing of the Company,s lead compound, ... "Special Pathogens," against which currently there are no ... Spring Bank,s proprietary Small Molecule Nucleic Acid ...
    (Date:9/18/2014)... , Sept. 18, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced that ... Dr. Geert Cauwenbergh , will present ... America™ Conference on Wednesday, September 24, 2014 ...
    (Date:9/17/2014)... -- DeepResearchReports.com adds "2014 Market Research Report on ... Research Report on Global and China Isothiocyanate Industry" ... Photo - http://photos.prnewswire.com/prnh/20140917/146748 ... (MMA) Industry" is a professional and in-depth research ... Global Methyl Methacrylate (MMA) market. The report introduces ...
    Breaking Medicine Technology:Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 2Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 3Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 4Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 5
    ... Spencer Inc. (NYSE: CSA ) announced today ... of $0.10 per common share payable on October 20, 2010 ... covers the third quarter of 2010.   ... Spencer Inc. (NYSE: CSA ) is a fully-integrated, ...
    ... Pharmaceutical Company (NYSE:  KVa/KVb) announced today that it has ... ("FDA") of the successful completion of an inspection of ... product to market.  Under the Company,s Consent Decree, successful ... facilities are expected to be required before K-V is ...
    Cached Medicine Technology:Cogdell Spencer Inc. Declares Quarterly Dividend 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 3K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 4K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 5K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 6K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 7K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 8
    Hardy pituitary spoon, bayonet, malleable....
    Cushing pituitary spoons, malleable copper, silver plated....
    ... is pouncing on the T.L.I.F. market as the ... of CFRP clinical history and the amazing success ... Leopard is sure to be king of the ... from 7-18 mm in height. The footprint is ...
    ... an Anterior Spinal Implant system. Material that ... of cortical bone. The result is an ... anterior column support, while optimizing the fusion ... Incorporates an anatomic design with 5 and ...
    Medicine Products: